MaxCyte, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
MaxCyte, Inc. (MXCT) reported Revenue from Contract with Customer, Excluding Assessed Tax of $4.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- MaxCyte, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $4.94M, a 15.25% decline year-over-year.
- MaxCyte, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $4.50M, a 21.63% decline year-over-year.
- MaxCyte, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $4.79M, a 20.94% decline year-over-year.
- MaxCyte, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $4.60M, a 17.98% decline year-over-year.
- MaxCyte, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $20.96M, a 5.66% decline from fiscal 2024.
- MaxCyte, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $22.21M, a 13.94% increase from fiscal 2023.
- MaxCyte, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $19.50M, a 32.18% decline from fiscal 2022.
- MaxCyte, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $28.75M, a 33.27% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.94M 10-Q · filed 2026-08-13 | $9.44M 10-Q · filed 2026-08-13 | $14.22M derived: sum of 3 quarters · filed 2026-08-13 | $18.83M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $4.50M 10-Q · filed 2026-05-13 | $9.29M derived: sum of 2 quarters · filed 2026-05-13 | $13.89M derived: sum of 3 quarters · filed 2026-05-13 | $19.71M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $9.39M derived: sum of 2 quarters · filed 2026-03-25 | $15.21M derived: sum of 3 quarters · filed 2026-08-13 | $20.96M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $4.60M 10-Q · filed 2025-11-13 | $10.43M derived: sum of 2 quarters · filed 2026-08-13 | $16.17M 10-Q · filed 2025-11-13 | $22.23M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $5.82M 10-Q · filed 2026-08-13 | $11.57M 10-Q · filed 2026-08-13 | $17.62M derived: sum of 3 quarters · filed 2026-08-13 | $23.23M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $5.74M 10-Q · filed 2026-05-13 | $11.80M derived: sum of 2 quarters · filed 2026-05-13 | $17.41M derived: sum of 3 quarters · filed 2026-05-13 | $22.38M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $6.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $11.67M derived: sum of 2 quarters · filed 2026-03-25 | $16.63M derived: sum of 3 quarters · filed 2026-03-25 | $22.21M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $5.61M 10-Q · filed 2025-11-13 | $10.58M derived: sum of 2 quarters · filed 2025-11-13 | $16.16M 10-Q · filed 2025-11-13 | $20.92M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $4.96M 10-Q · filed 2025-08-06 | $10.55M 10-Q · filed 2025-08-06 | $15.30M derived: sum of 3 quarters · filed 2025-08-06 | $19.46M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | $5.58M 10-Q · filed 2025-05-08 | $10.34M derived: sum of 2 quarters · filed 2025-05-08 | $14.50M derived: sum of 3 quarters · filed 2025-05-08 | $20.12M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $4.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $8.91M derived: sum of 2 quarters · filed 2025-03-11 | $14.53M derived: sum of 3 quarters · filed 2025-03-11 | $19.50M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $4.16M 10-Q · filed 2024-11-06 | $4.16M 10-Q · filed 2023-11-08 | $9.78M derived: sum of 2 quarters · filed 2024-11-06 | $14.74M 10-Q · filed 2024-11-06 | $14.74M 10-Q · filed 2023-11-08 | $22.50M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $5.62M 10-Q · filed 2024-08-06 | $5.62M 10-Q · filed 2023-08-09 | $10.59M 10-Q · filed 2024-08-06 | $10.59M 10-Q · filed 2023-08-09 | $18.34M derived: sum of 3 quarters · filed 2024-08-06 | $25.49M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $4.96M 10-Q · filed 2024-05-07 | $4.96M 10-Q · filed 2023-05-10 | $12.72M derived: sum of 2 quarters · filed 2024-05-07 | $19.87M derived: sum of 3 quarters · filed 2024-05-07 | $26.85M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $7.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $14.91M derived: sum of 2 quarters · filed 2024-03-12 | $21.89M derived: sum of 3 quarters · filed 2024-03-12 | $28.75M 10-K · filed 2024-03-12 | $28.75M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $7.15M 10-Q · filed 2023-11-08 | $14.13M derived: sum of 2 quarters · filed 2023-11-08 | $20.99M 10-Q · filed 2023-11-08 | $28.50M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $6.98M 10-Q · filed 2023-08-09 | $13.84M 10-Q · filed 2023-08-09 | $21.34M derived: sum of 3 quarters · filed 2023-08-09 | $26.95M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $6.86M 10-Q · filed 2023-05-10 | $14.36M derived: sum of 2 quarters · filed 2023-05-10 | $19.97M derived: sum of 3 quarters · filed 2023-05-10 | $24.19M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $7.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $13.11M derived: sum of 2 quarters · filed 2023-03-15 | $17.33M derived: sum of 3 quarters · filed 2023-03-15 | $21.57M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $5.61M 10-Q · filed 2022-11-09 | $9.83M derived: sum of 2 quarters · filed 2022-11-09 | $14.07M 10-Q · filed 2022-11-09 | $19.21M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $4.22M 10-Q · filed 2022-08-10 | $8.46M 10-Q · filed 2022-08-10 | $13.60M derived: sum of 3 quarters · filed 2022-08-10 | $18.27M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | $4.24M 10-Q · filed 2022-05-09 | $9.38M derived: sum of 2 quarters · filed 2022-05-09 | $14.05M derived: sum of 3 quarters · filed 2022-05-09 | $16.38M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $5.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $9.81M derived: sum of 2 quarters · filed 2022-03-22 | $12.14M derived: sum of 3 quarters · filed 2022-03-22 | $15.45M 10-K · filed 2022-03-22 | ||||
| 2020-09-30 | $4.67M 10-Q · filed 2021-11-10 | $7.00M derived: sum of 2 quarters · filed 2021-11-10 | $10.31M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $2.33M 10-Q · filed 2021-09-13 | $5.64M 10-Q · filed 2021-09-13 | ||||||
| 2019-12-31 | $13.26M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |